Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLM2010 for prevention of chemotherapy-induced nausea and vomiting
NCT07081256Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QLM2010 in chemotherapy-induced nausea and vomiting (CINV), sponsored by Qilu Pharmaceutical. Started Jan 2025; status: completed.
02
Drugs
QLM2010
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07081256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081256.